New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
14:25 EDTABT, ABT, ATRC, ATRC, BSX, BSX, EW, EW, MDT, MDT, STJ, STJ, VOLC, VOLCLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
News For ABT;ATRC;BSX;EW;MDT;STJ;VOLC From The Last 14 Days
Check below for free stories on ABT;ATRC;BSX;EW;MDT;STJ;VOLC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 15, 2014
16:08 EDTBSXBoston Scientific says REPRISE II data show sustained safety, performance
New data from the Boston Scientific clinical trial program of the LotusValve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. In REPRISE II, key one-year results include the following: Mean aortic valve pressure gradient remained low and stable at 12.6 + 5.7 mmHg. More than 86% of patients had no paravalvular aortic regurgitation by independent core lab assessment. In addition, no cases of moderate or severe paravalvular aortic regurgitation occurred. Mild and trace paravalvular aortic regurgitation rates were low at 11.4 and 2.3%, respectively. Cardiovascular mortality rate was 6.7%. Disabling stroke rate was 3.4%. No cases of non-study valve implantation, unplanned use of cardiopulmonary bypass, valve embolization, valve-in-valve or ectopic valve placement occurred.
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
08:06 EDTMDTMedtronic announces SEEQ wearable cardiac monitoring system in U.S.
Subscribe for More Information
08:02 EDTSTJSt. Jude Medical announces launch of OPTISTM integrated system
St. Jude Medical announced the company has secured CE Mark and FDA clearance for the new OPTISTM Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention optimization via direct installation into a hospital’s cardiac catheterization laboratory, fully integrating optical coherence tomography and fractional flow reserve into PCI workflow.
07:45 EDTEW, STJ, ABT, BSX, MDTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
07:21 EDTMDT, STJHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
13:18 EDTEWEdwards Lifesciences presents five-year clinical outcomes of PARTNER trial
Edwards Lifesciences announced the presentation of five-year clinical outcomes for inoperable patients treated in The PARTNER Trial, the world's only prospective randomized trial for transcatheter aortic valve replacement, TAVR, in patients deemed too sick for open-heart surgery. The data were presented as part of the late-breaking clinical trials session at the 26th Transcatheter Cardiovascular Therapeutics, TCT, the annual scientific symposium of the Cardiovascular Research Foundation."These longer term results from PARTNER's inoperable cohort indicated that TAVR was associated with a continued significant mortality benefit, persistent symptom benefit and a statistically significant reduction in rehospitalizations," said Michael J. Mack, M.D., chair, cardiovascular service line, Baylor Scott & White Health. "It is reassuring now five years later that in this very ill and elderly patient group facing a high likelihood of mortality, more patients treated with SAPIEN experienced sustained improvements in functional heart status and fewer repeat hospitalizations – two measures that signify an improvement in quality of life." "This was the first study of its kind for transcatheter heart valves," said Mack. "The PARTNER Trial has historical significance in the development of TAVR and continues to provide the clinical community with important information about the durability and performance of the Edwards SAPIEN valves."
September 13, 2014
18:16 EDTSTJSt. Jude Medical announces data from the EnligHTN III study
St. Jude Medical announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. The results were presented during the 26th annual Transcatheter Cardiovascular Therapeutics scientific symposium.
16:47 EDTMDTMedtronic CoreValve provides positive outcomes out two years in risky patients
Medtronic announced new data showing that transcatheter aortic valve replacement, TAVR, with the CoreValve System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Without treatment, these patients had a 50% chance of death at one year.
September 12, 2014
15:03 EDTSTJ, MDT, BSX, EWSt. Jude Medical pausing Portico sales, implants, says Wells Fargo
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
10:00 EDTEW, MDTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Airgas (ARG) initiated with a Neutral at Northcoast... CBOE Holdings (CBOE) initiated with a Buy at Deutsche Bank... CME Group (CME) initiated with a Buy at Deutsche Bank... Colfax (CFX) initiated with a Neutral at Northcoast... Corporate Office Properties (OFC) initiated with an Overweight at Capital One... Edwards Lifesciences (EW) initiated with a Buy at Sterne Agee... Energen (EGN) initiated with a Buy at Deutsche Bank... Goodrich Petroleum (GDP) initiated with an Outperform at Cowen... GreenHunter Resources (GRH) initiated with a Hold at Stifel... GrubHub (GRUB) initiated with a Market Perform at Barrington... Illinois Tool Works (ITW) initiated with a Neutral at Northcoast... IntercontinentalExchange (ICE) initiated with a Hold at Deutsche Bank... JD.com (JD) initiated with a Buy at Brean Capital... Lincoln Electric (LECO) initiated with a Buy at Northcoast... Live Nation (LYV) initiated with a Buy at Jefferies... Medtronic (MDT) initiated with a Neutral at Sterne Agee... Midstates Petroleum (MPO) initiated with a Market Perform at Cowen... NASDAQ (NDAQ) initiated with a Hold at Deutsche Bank... Newfield Exploration (NFX) initiated with an Outperform at Iberia... Newpark Resources (NR) initiated with an Outperform at Credit Suisse... Nuverra Environmental (NES) initiated with a Buy at Stifel... Palo Alto (PANW) initiated with a Buy at Roth Capital... Petrobras (PBR) initiated with an Outperform at Cowen... RSP Permian (RSPP) initiated with a Hold at Deutsche Bank... Sensata (ST) initiated with an Equal Weight at Morgan Stanley... Stage Stores (SSI) initiated with a Neutral at Credit Suisse... Synergy Resources (SYRG) initiated with an Outperform at Cowen... TE Connectivity (TEL) initiated with an Overweight at Morgan Stanley... Twitter (TWTR) initiated with a Buy at Canaccord... Walter Investment (WAC) initiated with an Underweight at Barclays... Washington REIT (WRE) initiated with an Equalweight at Capital One... Yandex (YNDX) initiated with a Buy at Canaccord... Yara International (YARIY) initiated with a Neutral at Credit Suisse.
08:11 EDTMDTMedtronic Noncompliant Balloon Dilatation Catheter receives FDA clearance
Medtronic announced the FDA 510(k) clearance and launch of the NC Euphora Noncompliant Balloon Dilatation Catheter. Following drug-eluting stent implantation to reopen a narrowed artery, a noncompliant balloon is inflated with high pressure to ensure that the stent is fully apposed in order to facilitate transfer of the drug to the artery wall. Stent under-expansion has been defined as a major risk factor for both artery re-narrowing, or restenosis, and the potential formation of blood clots, known as stent thrombosis. Postdilatation with noncompliant balloons has been recommended to overcome these complications and provide optimal stent expansion after stent placement.
September 10, 2014
16:09 EDTEWEdwards Lifesciences initiated with a Buy at Sterne Agee
Subscribe for More Information
16:09 EDTMDTMedtronic initiated with a Neutral at Sterne Agee
Target $68.
09:32 EDTMDTMedtronic announces first U.S. implants in CoreValve Evolut R study
Subscribe for More Information
September 9, 2014
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
07:26 EDTSTJ, BSXMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use